Physician profile
Ryan Gerald Davis
NPI 1639823362
$4,300.84
in general payments reported to CMS, 2019-2025
33 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $123 · 2023: $833 · 2024: $1,753 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,177.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $734.27 | 2023-2025 | Evenity, Repatha, Repatha |
| Abbvie INC. | $610.86 | 2023-2025 | |
| Lilly USA, LLC | $372.71 | 2023-2025 | Mounjaro, Kisunla, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $277.96 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $272.10 | 2023-2025 | Spravato |
| Indivior INC. | $243.98 | 2023-2024 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $194.97 | 2022-2025 | Caplyta |
| Astellas Pharma US INC | $172.12 | 2024-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $166.20 | 2023-2025 | |
| Braeburn INC. | $129.57 | 2023-2024 | Brixadi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.06 | 2023-2024 | Synjardy, Jardiance, Tradjenta |
| Sumitomo Pharma America, INC. | $120.35 | 2023-2025 | Gemtesa |
| Novo Nordisk INC | $102.17 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $98.83 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $94.72 | 2024-2025 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $59.98 | 2023-2025 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $56.02 | 2024-2025 | |
| Edwards Lifesciences Corporation | $49.45 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Idorsia Pharmaceuticals US INC | $46.86 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $43.24 | 2025 | Auvelity |
| Daiichi Sankyo INC. | $42.59 | 2023-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $41.74 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Neurocrine Biosciences, INC. | $37.29 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.21 | 2024 | Relistor |
| Phathom Pharmaceuticals, INC. | $30.14 | 2024-2025 | Voquezna |
| Pfizer INC. | $28.67 | 2024-2025 | |
| Dexcom, INC. | $21.09 | 2025 | Dexcom G6 Transmitter |
| Actelion Pharmaceuticals US, INC. | $17.74 | 2025 | Uptravi |
| Currax Pharmaceuticals LLC | $16.83 | 2024 | Contrave |
| Lundbeck LLC | $16.58 | 2025 | Rexulti |
| Tactile Systems Technology INC | $14.13 | 2025 | Flexitouch Plus, Nimbl |
| Grifols USA, LLC | $13.53 | 2023 | Prolastin-C Liquid |
| Organon LLC | $10.88 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.